Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Thoracic 1Other 1Gynecologic 1Dermatologic 1Classical hematology 1CNS 1

Conditions

Anemia, Refractory, with Excess of Blasts 271Leukemia, Myeloid, Acute 258Myelodysplastic Syndromes 254Anemia 245Leukemia 228Neoplasms 211Precursor Cell Lymphoblastic Leukemia-Lymphoma 182Leukemia, Myelomonocytic, Chronic 151Multiple Myeloma 138Venous Thromboembolism 137Myeloproliferative Disorders 131Leukemia, Lymphocytic, Chronic, B-Cell 126Lymphoma 119Lymphoma, Non-Hodgkin 118Thrombocytopenia 117Hodgkin Disease 103Anemia, Aplastic 97Febrile Neutropenia 86Hematologic Neoplasms 82Anemia, Refractory 82Primary Myelofibrosis 81Lymphoma, Follicular 81Congenital Abnormalities 81Leukemia, Myeloid, Chronic-Phase 74Leukemia, Myelogenous, Chronic, BCR-ABL Positive 73Blast Crisis 72Leukemia, Myeloid, Accelerated Phase 69Lymphoma, Mantle-Cell 68Neoplasms, Plasma Cell 66Myelodysplastic-Myeloproliferative Diseases 65

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Arthritis, Juvenile × Classical hematology × Clear all
NCT01206907 2012-08-17

Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Opioid Tolerant Pediatric Subjects

Endo Pharmaceuticals

Phase 3 Withdrawn
Classical hematology

Anemia, Sickle Cell, Arthritis, Juvenile, Neoplasms, Chronic Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡